Intra Cellular Therapies reported $0 in Loan Capital for its first fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Loan Capital Change
Acadia Pharmaceuticals ACAD:US $ 0M 0M
ALKERMES ALKS:US 292.17M 633K
Aptinyx Inc APTX:US $ 24.29M 10.14M
Biocryst Pharmaceuticals BCRX:US $ 604.46M 19M
Biogen BIIB:US $ 6275.7M 1.7M
Bristol Myers Squibb BMY:US $ 37450M 2155M
Cytokinetics CYTK:US $ 197.08M 54.24M
Esperion Therapeutics ESPR:US $ 258.68M 398K
Gilead Sciences GILD:US $ 25183M 4M
Halozyme Therapeutics HALO:US $ 788.1M 0.84M
Intra Cellular Therapies ITCI:US $ 0M 0M
JAZZ PHA JAZZ:US $ 5992.87M 32.34M
Johnson & Johnson JNJ:US $ 28851M 1134M
Marinus Pharmaceuticals MRNS:US $ 69.93M 29.12M
Minerva Neurosciences NERV:US $ 0M 0M
Nektar Therapeutics NKTR:US $ 0M 0M
Neurocrine Biosciences NBIX:US $ 377.7M 42.6M
Novartis NVS:US $ 24373M 150M
Prothena PRTA:US 0 0
Supernus Pharmaceuticals SUPN:US $ 400.38M 21.13M
United Therapeutics UTHR:US $ 800M 0M
Vanda Pharmaceuticals VNDA:US $ 0M 0M